Search
Cancer Clinical Trials in Salt Lake City, UT
A listing of 130 Cancer clinical trials in Salt Lake City, UT actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
49 - 60 of 130
The city of Salt Lake City, Utah, currently has 130 active clinical trials seeking participants for Cancer research studies.
Featured Trial
Lung or Breast Cancer Treatment
Recruiting
Diagnosed w/ Lung or Breast Cancer - Underwent Cancer Treatment, Take a step towards hope and healing. Enroll now in our clinical trial for an innovative breast and lung cancer treatment
Conditions:
Cancer
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Non-Small Cell Lung Cancer Treatment
Recruiting
A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations
Conditions:
NSCLC
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma
Non-Small-Cell Lung
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Recruiting
The goal of this study is to evaluate if adding community services navigation to the standard referral process for social needs is an effective and scalable strategy for addressing disparities in follow-up to abnormal breast cancer screening results. The investigators will determine the effectiveness of social needs referrals combined with a community services navigation intervention in the screening mammography setting to improving breast screening outcomes in underserved women.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences, Salt Lake City, Utah
Conditions: Breast Cancer
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
Recruiting
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: University of Utah Sugarhouse Health Center, Salt Lake City, Utah +1 locations
Conditions: Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Recruiting
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research h... Read More
Gender:
Female
Ages:
Between 25 years and 55 years
Trial Updated:
05/22/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Recruiting
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Recruiting
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Colorectal Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Utah Cancer Specialists, Salt Lake City, Utah
Conditions: Metastatic Non Small Cell Lung Cancer
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
Recruiting
BDTX-4933-101 is a first-in-human, open-label, Phase 1 dose escalation and an expansion cohort study designed to evaluate the safety and tolerability, maximum tolerated dose (MTD) and the preliminary recommended Phase 2 dose (RP2D), and antitumor activity of BDTX-4933. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC) harboring KRAS non-G12C mutations or BRAF mutations, advanced/metastatic melanom... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: Huntsman Cancer Institute (University of Utah), Salt Lake City, Utah
Conditions: Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, Melanoma, Melanoma (Skin), BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Lung Cancer, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
Recruiting
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.
After completion of cohort 1 (108 participants),... Read More
Gender:
All
Ages:
All
Trial Updated:
05/17/2024
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah +1 locations
Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma, Uterine Corpus Sarcoma
REFLECTION: A Clinical Practice Learning Program for Galleri®
Recruiting
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 17,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Gender:
All
Ages:
22 years and above
Trial Updated:
05/17/2024
Locations: VA Salt Lake City Health Care System (VASLCHCS), Salt Lake City, Utah
Conditions: Early Detection of Cancer, Cancer
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
Recruiting
Determine the effects of the Computerized Symptom Assessment Tool (C-SCAT) versus usual care on the primary outcomes of self-efficacy for symptom management and symptom self-management behaviors
Gender:
All
Ages:
Between 15 years and 29 years
Trial Updated:
05/17/2024
Locations: University of Utah Primary Children's Hospital, Salt Lake City, Utah
Conditions: Symptoms and Signs, Cancer, Childhood Cancer
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Recruiting
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab in patients with metastatic or advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
49 - 60 of 130